Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 318-334

  Klebanoff, Christopher A ^a   Scott, Christopher D ^a   Leonardi, Anthony J ^a   Yamamoto, Tori N ^a,b   Cruz, Anthony C ^c   Ouyang, Claudia ^c   Ramaswamy, Madhu ^c,d   Roychoudhuri, Rahul ^a   Ji, Yun ^a,e   Eil, Robert L ^a   Sukumar, Madhusudhanan ^a   Crompton, Joseph G ^a   Palmer, Douglas C ^a   Borman, Zachary A ^a   Clever, David ^a,f   Thomas, Stacy K ^c   Patel, Shashankkumar ^a,g   Yu, Zhiya ^a   Muranski, Pawel ^a,e   Liu, Hui ^e   Wang, Ena ^e,h   Marincola, Francesco M ^e,h   Gros, Alena ^a   Gattinoni, Luca ^a,e   Rosenberg, Steven A ^a   Siegel, Richard M ^c   Restifo, Nicholas P ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d MEDIMMUNE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD27 ANTIGEN; CD3 ANTIBODY; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS ANTIGEN; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; GRANZYME B; HEXOKINASE; HISTONE H3; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR ALPHA; KRUPPEL LIKE FACTOR 2; PROTEIN KINASE B; PROTEIN S6; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR FKHR; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; FAS LIGAND; FAS PROTEIN, MOUSE;

ADOPTIVE CELL TRANSFER; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL COMMUNICATION; CELL DIVISION; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; CELL TRANSFER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOLYSIS; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOCYTE DIFFERENTIATION; MELANOMA B16; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD95; CELL DIFFERENTIATION; FAS LIGAND PROTEIN; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; T-LYMPHOCYTES;

EID: 84956642934     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81217     Document Type: Article

References (78)

1. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014;32:189-225.
2. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 2014;257(1):127-144.
3. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68.
4. Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J. 2009;15(6):451-455.
5. Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev. 2014;258(1):12-29.
6. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9(9):510-519.
7. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044.
8. Kershaw MH, Westwood JA, Darcy PK. Geneengineered T cells for cancer therapy. Nat Rev Cancer. 2013;13(8):525-541.
9. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9(10):704-716.
10. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107-126.
11. Hinrichs CS, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A. 2009;106(41):17469-17474.
12. Cieri N, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573-584.
13. Hinrichs CS, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117(3):808-814.
14. Casati A, et al. Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. 2013;62(10):1563-1573.
15. Xu Y, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. Blood. 2014;123(24):3750-3759.
16. Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.
17. Louis CU, et al. Antitumor activity and longterm fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6056.
18. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
19. Linnemann C, Schumacher TN, Bendle GM. T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol. 2011;131(9):1806-1816.
20. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651-660.
21. Sabatos CA, et al. A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction. Immunity. 2008;29(2):238-248.
22. Gerard A, et al. Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells. Nat Immunol. 2013;14(4):356-363.
23. Maciver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259-283.
24. Overwijk WW, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569-580.
25. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
26. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
27. Gattinoni L, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808-813.
28. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Cancer. 2012;12(10):671-684.
29. Rufer N, et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood. 2003;102(5):1779-1787.
30. Mackall CL, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89(10):3700-3707.
31. Schober SL, Kuo CT, Schluns KS, Lefrancois L, Leiden JM, Jameson SC. Expression of the transcription factor lung Kruppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. J Immunol. 1999;163(7):3662-3667.
32. Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-betmediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity. 2012;36(3):374-387.
33. Joshi NS, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27(2):281-295.
34. Rutishauser RL, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31(2):296-308.
35. Martin MD, Wirth TC, Lauer P, Harty JT, Badovinac VP. The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells. J Immunol. 2011;187(6):2923-2931.
36. Kedl RM, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med. 2000;192(8):1105-1113.
37. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271-285.
38. Russ BE, et al. Distinct epigenetic signatures delineate transcriptional programs during virusspecific CD8(+) T cell differentiation. Immunity. 2014;41(5):853-865.
39. Peter ME, et al. The CD95 receptor: apoptosis revisited. Cell. 2007;129(3):447-450.
40. Alderson MR, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993;178(6):2231-2235.
41. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med. 2000;6(8):920-923.
42. Kleber S, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008;13(3):235-248.
43. Corsini NS, et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell. 2009;5(2):178-190.
44. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356(6367):314-317.
45. Ramaswamy M, et al. Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains. Cell Death Differ. 2011;18(4):712-720.
46. Chakrabandhu K, et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 2007;26(1):209-220.
47. Feig C, Tchikov V, Schutze S, Peter ME. Palmitoylation of CD95 facilitates formation of SDSstable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007;26(1):221-231.
48. Macintyre AN, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity. 2011;34(2):224-236.
49. Kerdiles YM, et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol. 2009;10(2):176-184.
50. Fabre S, et al. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol. 2008;181(5):2980-2989.
51. Kelly AP, et al. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J. 2007;26(14):3441-3450.
52. John S, Weiss JN, Ribalet B. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS One. 2011;6(3):e17674.
53. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23(20):7315-7328.
54. Sukumar M, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 2013;123(10):4479-4488.
55. Crompton JG, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75(2):296-305.
56. Jensen MC, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Blood Marrow Transplant. 2010;16(9):1245-1256.
57. Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
58. Kochenderfer JN, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
59. Klebanoff CA, et al. Central memory self/ tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571-9576.
60. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117(6):1888-1898.
61. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. Invest. 2008;118(1):294-305.
62. Graef P, et al. Serial transfer of single-cellderived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014;41(1):116-126.
63. Stemberger C, et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS One. 2012;7(4):e35798.
64. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood. 2012;119(1):72-82.
65. Sun M, Ames KT, Suzuki I, Fink PJ. The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol. 2006;177(3):1481-1491.
66. Frauwirth KA, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-777.
67. Sung JH, et al. Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes. Cell. 2012;150(6):1249-1263.
68. Chtanova T, et al. Dynamics of T cell, antigenpresenting cell, and pathogen interactions during recall responses in the lymph node. Immunity. 2009;31(2):342-355.
69. Guarda G, et al. L-selectin-neagtive CCR7-effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol. 2007;8(7):743-752.
70. Martin MD, Condotta SA, Harty JT, Badovinac VP. Population dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo. J Immunol. 2012;188(3):1255-1265.
71. Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med. 2012;2(11):a012427.
72. Butler TC, Kardar M, Chakraborty AK. Quorum sensing allows T cells to discriminate between self and nonself. Proc Natl Acad Sci U S A. 2013;110(29):11833-11838.
73. Reynolds J, Amado IF, Freitas AA, Lythe G, Molina-París C. A mathematical perspective on CD4 T cell quorum-sensing. J Theor Biol. 2014;347:160-175.
74. Thaventhiran JE, et al. Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proc Natl Acad Sci U S A. 2012;109(33):E2223-E2229.
75. Amado IF, et al. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med. 2013;210(12):2707-2720.
76. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17-27.
77. Klebanoff CA, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Cancer Res. 2011;17(16):5343-5352.
78. Gattinoni L, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115(6):1616-1626.